Phase I–II clinical studies have demonstrated that giredestrant has promising clinical and pharmacodynamic activity, as monotherapy and in combination with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib, and is well tolerated by patients with ER+, HER2– BC [34, 36–43]. This evidence concerns the gene ERBB2 and breast cancer.